Leukemia and lymphoma are both hematologic malignancies, meaning that they involve the blood or bone marrow. The American Cancer Society […]
The United States Food and Drug Administration (FDA) has approved Arzerra® (ofatumumab) as maintenance therapy for the treatment of advanced […]
CancerConnect Presents: Ask the Expert: Blood Cancer Treatment Progress & What’s Next In this informative web chat, Jacqueline Barrientos, MD […]
Sun Valley, ID & Fort Worth, TX– OMNI Health Media (OMNI) announces the launch of blood cancer educational programs for […]
Among older people with chronic lymphocytic leukemia (CLL) and other health problems, initial treatment with Gazyva® (obinutuzumab) and chlorambucil was […]
The drug ibrutinib was well tolerated and highly effective in patients with untreated, relapsed and unresponsive chronic lymphocytic leukemia—leading to […]
Individuals with lymphoma or those who have undergone organ transplants are far more likely than the average person to develop—and […]
Caring for Yourself During Chemotherapy for Leukemia: How to Manage Hair Loss, Dry Skin, and Brittle Nails
Chemotherapy can be effective treatment for cancer but may also cause physical side effects that may be uncomfortable and affect […]
A study of “chemo brain”—the foggy thinking and forgetfulness that patients may experience after chemotherapy—suggests that the condition improves substantially […]
Survivors of non-central nervous system (CNS) childhood cancers reported a statistically and clinically significantly higher rate of neurocognitive impairment than […]
The combination of Arzerra™ (ofatumumab), Fludara® (fludarabine), and Cytoxan® (cyclophosphamide) shows promising effectiveness in the initial treatment of chronic lymphocytic leukemia (CLL). These results were presented at the 2009 annual meeting of the American Society of Hematology.
According to the results of a Phase II clinical trial, the combination of Treanda® (bendamustine) and Rituxan® (rituximab) is effective and safe for the initial treatment of patients with advanced chronic lymphocytic leukemia (CLL). These results were presented at the 2009 annual meeting of the American Society of Hematology.
The targeted therapy Arzerra™ (ofatumumab) has been granted accelerated approval by the U.S. Food and Drug Administration for treatment of […]
As the month of September brings leukemia and lymphoma into focus, it’s time to increase public understanding of these diseases, including their prevalence, approaches to screening and prevention, treatment options, and resources that offer updated leukemia and lymphoma information throughout the year.
Industrial workers who are exposed to formaldehyde may be at an increased risk of dying from blood and lymphatic cancers, particularly myeloid leukemia but also Hodgkin’s lymphoma and multiple myeloma, according to the results of a study published in the Journal of the National Cancer Institute.
Sequential Treatment with Fludara®, Cytoxan®, and Rituxan® Produces High-quality Responses in CLL Patients with chronic lymphocytic leukemia (CLL) treated with […]
FCR-Lite Is Safe and Effective in Previously Untreated CLL FCR-Lite, a drug regimen that consists of Fludara® (fludarabine), Cytoxan® (cyclophosphamide), […]
The American Society of Clinical Oncology 2008: Advances in Treatment of Lymphoma and Chronic Lymphocytic Leukemia
The American Society of Clinical Oncology 2008: Advances in Treatment of Lymphoma and Chronic Lymphocytic Leukemia At the 2008 meeting […]